compound 1 has resulted in the identification of a potent and selectiveCandidaalbicansN-myristoyltransferase (CaNmt) inhibitor RO-09-4609, which exhibits antifungal activity against C. albicans in vitro. Further modification of its C-2 substituent has led to the discovery of RO-09-4879, which exhibits antifungal activity in vivo. The drug design is based on X-ray crystal analysis of a CaNmt complex
The present invention is directed to new bicyclic compounds of formula (I), and pharmaceutically acceptable salts thereof wherein R?1, R2, R3, R4, R5, R6, R7, Q1 Q2 and Q3¿ are as defined in the claims. The compounds have N-myristoyltransferase inhibitory and antifungal activity.